Ketorolac tromethamine

RIKEDOL is indicated in the short-term (up to 2 days) management of moderate to severe acute pain after surgery; in case of highly severe pain, IV ketorolac can be administered as continuation treatment following opioid analgesic, if necessary; management of pain caused by kidney stones.

Solution (30 mg/ml) for i.m. or i.v. injection

Farmaceutici S.p.A.

Find out our Corporate Website:

Go to the website

Fidia’s other websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Middle East product portfolio focalizes primarily on therapeutic areas such as joint healthcare and tissue repair.

Fidia Pharma Middle East is focused on providing consumers with innovative products that offer quality, safety and performance and exploring innovative channel strategies to access customers and consumers, such as healthcare e-commerce.